oasis 1 oral semaglutide 50 mg nejm 2023 obesity at a Dose of 25 in Adults with Overweight or Drug Watch: The oral version

Silico Pharmacol

The 2020 Aging Pathobiology and Therapeutics review (PMID 35083444) framed the broader anti-ageing framing under which oxidative-stress findings are typically grouped

semaglutide 2.4 mg as a treatment option for adults with obesity

McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J (2016) Health-related quality of life measured using the EQ-5D-5L: South Australian population norms

If somebody comes in with a BMI over 30 and you dont treat it, thats Tuesday. He thinks some of the hesitancy for treating patients with obesity medications comes from the history of dangerous weight loss drugs

Microdosing GLP-1 medications lacks clinical evidence, meaning doctors dont have enough reliable data to confirm whether lower than approved doses are effective